Efficacy of dendritic cell vaccines based on type I dendritic cells: results of clinical trials

References

[1] Моисеенко В.М., Балдуева И.А., Орлова Р.В. и др. Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных с солидными опухолями. Патент РФ RU2267326.

[2] Banchereau J., Briere F., Caux C. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2OOO; 18: 767-811.

[3] Felzmann T., Gadner H., Holter W. Dendritic cells as adjuvants in antitumor immune therapy. Onkologie. 2002; 25: 456-64.

[4] Geiger J.D., Hutchinson R.J., Hohenkirk L.F. et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61: 8513-9.

[5] Dagher R., Long L.M., Read E.J. et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med. Pediatr. Oncol. 2002; 38: 158-64.

[6] Labeur M.S., Roters B., Pers B. et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999; 162:168-75.

[7] Mazzaccaro R.J., Gedde M., Jensen E.R. et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. PNAS. 1996; 93:11786-91.

[8] Simmons C.P., Mastroeni P., Fowler R. et al. MHC class l-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol. 1999; 163: 6502-10.

[9] Cho H.J., Takabayashi K., Cheng P.M. et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol. 2000; 18: 509-14.

[10] Ridge J.P., Di-Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998; 393: 474-8.

[11] Sigal L.J., Crotty S., Andino R., Rock K.L. Cytotoxic T-cell immunity to virus- infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 1999;398:77-80.

[12] Liu Y.-J., Kanzler H., SoumelisV., Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2001; 2: 585-9.

[13] Kalinski P., Hilkens C.M., Wierenga E.A., Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999; 20: 561-7.

[14] Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989;7: 145-73.

[15] Felzmann T., Hüttner K.G., Breuer S.K. et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol. Immunother. 2005; 54: 769-80.

[16] Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 2000; 1:311-6.

RIGHTS & PERMISSIONS

Eco-Vector